Feinstein Institutes Hires Top Dermatologist as First Chief Biotechnology Officer
Event summary
- Brian S. Kim, MD, MTR, joins Feinstein Institutes as first Chief Biotechnology Officer and head of intellectual asset management.
- Kim brings expertise in bioelectronic medicine, neuroimmunology, and biotech entrepreneurship from Icahn School of Medicine at Mount Sinai.
- He has authored over 190 peer-reviewed publications and co-founded three biotech companies.
- Kim will oversee strategic development of biotechnology initiatives and intellectual property assets.
The big picture
Feinstein Institutes' hiring of Kim underscores its commitment to advancing bioelectronic medicine, a field that uses electrical stimulation to treat disease. This strategic move comes as the institute builds on its 2025 FDA approval for a vagus nerve stimulation implant for rheumatoid arthritis. The appointment signals an intensified push toward commercializing cutting-edge research in neuroimmunology and biotechnology.
What we're watching
- Strategic Focus
- How Kim's appointment will accelerate the translation of bioelectronic medicine research into commercial treatments.
- Intellectual Property
- Whether Feinstein Institutes can leverage Kim's patent portfolio to drive new revenue streams.
- Industry Leadership
- The pace at which bioelectronic medicine gains mainstream adoption in treating inflammatory conditions.